By Colin Kellaher

AbbVie Inc. (ABBV) on Tuesday said the European Commission approved Skyrizi for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

The North Chicago, Ill., biopharmaceutical company said Skyrizi showed high rates of skin clearance at 16 weeks in clinical studies, with the clearance durable at one year.

Skyrizi is part of a collaboration between AbbVie and German pharmaceutical company Boehringer Ingelheim. AbbVie is leading development and commercialization of the drug world-wide.

AbbVie earlier this month received U.S. and Canadian regulatory approval for the drug in adults with moderate to severe plaque psoriasis.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 30, 2019 13:34 ET (17:34 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024 Click Here for more AbbVie Charts.